Smith & Nephew PLC (LSE: SN.)

Smith & Nephew PLC (LSE: SN.) is an FTSE 100-listed global medical technology company. It specializes in the development, manufacturing, and commercialization of innovative medical devices for the repair, regeneration, and replacement of soft and hard tissue.

Key Investment Rationale – Buy at GBX 1,259.00

• Revenue Growth Across All Divisions and Regions: Smith+Nephew delivered broad-based top-line expansion, with underlying revenue growth of 5.0% in H1 and 6.7% in Q2 2025, despite fewer trading days compared to the prior year. All three business units — Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management — reported sequential acceleration, highlighting solid demand and operational execution. The Advanced Wound Management segment stood out with double-digit underlying growth of 10.2%, supported by a rebound in Advanced Wound Bioactives and decent uptake in wound devices. This performance indicates a successful return to growth across the company’s diversified portfolio.
• Improved Profitability and Exceptional Cash Generation: The company achieved significant progress in operational efficiency, with trading profit up 11.2% and operating profit rising 30.6% year-over-year. Trading profit margin expanded by 100 basis points to 17.7%, reflecting better cost control and revenue leverage. Cash generation was a standout metric — cash from operations rose 54% to $568 million, and free cash flow surged more than sixfold to $244 million. These results underline Smith+Nephew’s ability to translate growth into decent profitability and liquidity, providing a firm foundation for future investment and shareholder returns.
• Sustained Innovation Driving Market Competitiveness: Innovation continues to be a major differentiator for Smith+Nephew. Impressively, three-quarters of H1 revenue growth came from products launched in the past five years. The company introduced several new products across all business units — including LEGION◊ knee inserts, TRIGEN◊ MAX Tibia Nailing System, and ALLEVYN◊ Ag+ SURGICAL dressings — expanding its technology leadership in both orthopaedics and wound care. With a robust pipeline of upcoming launches and a focus on evidence-based adoption, the firm is well positioned to maintain its momentum and deliver long-term growth.

SN. Daily Chart & Valuation

 One Year Technical Price Chart (as of November 11, 2025). Source: REFINITIV, Analysis: Kalkine Group

For conducting the valuation, the following peers have been considered: Convatec Group PLC (LSE: CTEC), AstraZeneca PLC (LSE: AZN), etc.

As per the above-mentioned price action and technical indicators analysis, a ‘Buy’ rating has been given on Smith & Nephew PLC (LSE: SN.) at the Current Market Price of GBX 1,259.00, as of November 11, 2025, at 11:20 AM GMT.

Markets are trading in a highly volatile zone currently due to certain Macro & Micro-economic data and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels is 11 November 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level which the stock is expected to reach as per the relative valuation method and/or technical analysis taking into consideration both short-term and long-term scenario.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the London Stock Exchange (LSE) and or REFINITIV. Typically, both sources (LSE and or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.’

Note 6: Dividend Yield may vary as per the stock price movement.